Al-Dawaa Medical Services Company (4163.SR)
SAR 79.6
(-0.25%)
SAR 79.6
(-0.25%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 2.23 Billion SAR | -10.16% |
| 2022 | 2.49 Billion SAR | 16.03% |
| 2021 | 2.14 Billion SAR | 32.84% |
| 2020 | 1.61 Billion SAR | 30.16% |
| 2019 | 1.24 Billion SAR | 6.1% |
| 2018 | 1.17 Billion SAR | -2.75% |
| 2017 | 1.2 Billion SAR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 2.13 Billion SAR | -4.88% |
| 2024 Q2 | 2.1 Billion SAR | -1.1% |
| 2023 Q4 | 2.23 Billion SAR | -0.17% |
| 2023 FY | 2.23 Billion SAR | -10.16% |
| 2023 Q3 | 2.24 Billion SAR | -3.97% |
| 2023 Q2 | 2.33 Billion SAR | -3.11% |
| 2023 Q1 | 2.41 Billion SAR | -3.28% |
| 2022 Q2 | 2.95 Billion SAR | 37.12% |
| 2022 FY | 2.49 Billion SAR | 16.03% |
| 2022 Q4 | 2.49 Billion SAR | -14.27% |
| 2022 Q3 | 2.9 Billion SAR | -1.54% |
| 2022 Q1 | 2.15 Billion SAR | 0.25% |
| 2021 Q1 | 38.09 Million SAR | -97.53% |
| 2021 FY | 2.14 Billion SAR | 32.84% |
| 2021 Q4 | 2.14 Billion SAR | 0.0% |
| 2021 Q2 | 1.43 Billion SAR | 3656.03% |
| 2020 Q1 | 85.04 Million SAR | 0.0% |
| 2020 Q3 | 1.54 Billion SAR | 0.0% |
| 2020 Q4 | 1.54 Billion SAR | 0.0% |
| 2020 FY | 1.61 Billion SAR | 30.16% |
| 2019 FY | 1.24 Billion SAR | 6.1% |
| 2018 FY | 1.17 Billion SAR | -2.75% |
| 2017 FY | 1.2 Billion SAR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Middle East Pharmaceutical Industries Co. | 44.67 Million SAR | -4914.12% |
| Nahdi Medical Company | 265.09 Million SAR | -744.957% |
| Al-Razi Medical Co. | 11.02 Million SAR | -20222.208% |
| Almujtama Alraida Medical Co. | 155.88 Million SAR | -1336.902% |